{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:16Z","timestamp":1790014696653,"version":"4.0.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001255","name":"Lister Institute of Preventive Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Clear cell renal cell carcinoma (ccRCC) represents the most common form of kidney cancer and is typified by biallelic inactivation of the von Hippel-Lindau (\n                    <jats:italic>VHL<\/jats:italic>\n                    ) tumour suppressor gene. Here, we undertake genome-wide CRISPR\/Cas9 screening to reveal synthetic lethal interactors of\n                    <jats:italic>VHL<\/jats:italic>\n                    , and uncover that loss of Core Binding Factor \u03b2 (CBF-\u03b2) causes cell death in\n                    <jats:italic>VHL<\/jats:italic>\n                    -null ccRCC cell lines and impairs tumour establishment and growth in vivo. This synthetic relationship is independent of the elevated activity of hypoxia inducible factors (HIFs) in\n                    <jats:italic>VHL<\/jats:italic>\n                    -null cells, but does involve the RUNX transcription factors that are known binding partners of CBF-\u03b2. Mechanistically, CBF-\u03b2 loss leads to upregulation of type I interferon signalling, and we uncover a direct inhibitory role for CBF-\u03b2 at the\n                    <jats:italic>STING<\/jats:italic>\n                    locus controlling Interferon Stimulated Gene expression. Targeting CBF-\u03b2 in kidney cancer both selectively induces tumour cell lethality and promotes activation of type I interferon signalling.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-70517-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:16:14Z","timestamp":1773310574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["VHL synthetic lethality screens uncover CBF-\u03b2 as a negative regulator of STING"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9384-5883","authenticated-orcid":false,"given":"James A. C.","family":"Bertlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tekle","family":"Pauzaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4330-5333","authenticated-orcid":false,"given":"Niek","family":"Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-189X","authenticated-orcid":false,"given":"James C.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-3417","authenticated-orcid":false,"given":"Jia Jhing","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3318-1851","authenticated-orcid":false,"given":"Nicholas J.","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4890-4685","authenticated-orcid":false,"given":"Anneliese O.","family":"Speak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6595-8995","authenticated-orcid":false,"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0248-1632","authenticated-orcid":false,"given":"James A.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"70517_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/bjc.2016.304","volume":"115","author":"CR Smittenaar","year":"2016","unstructured":"Smittenaar, C. R., Petersen, K. A., Stewart, K. & Moitt, N. Cancer incidence and mortality projections in the UK until 2035. Br. J. Cancer 115, 1147\u20131155 (2016).","journal-title":"Br. J. Cancer"},{"key":"70517_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA. Cancer J. Clin."},{"key":"70517_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2014.05.010","volume":"67","author":"FE Vera-Badillo","year":"2015","unstructured":"Vera-Badillo, F. E. et al. Systemic therapy for non\u2013clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur. Urol. 67, 740\u2013749 (2015).","journal-title":"Eur. Urol."},{"key":"70517_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.eururo.2014.04.029","volume":"67","author":"B Shuch","year":"2015","unstructured":"Shuch, B. et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur. Urol. 67, 85\u201397 (2015).","journal-title":"Eur. Urol."},{"key":"70517_CR5","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA. Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA. Cancer J. Clin."},{"key":"70517_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85\u201390 (1994).","journal-title":"Nat. Genet."},{"key":"70517_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"70517_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"70517_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ng.2891","volume":"46","author":"M Gerlinger","year":"2014","unstructured":"Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225\u2013233 (2014).","journal-title":"Nat. Genet."},{"key":"70517_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cell.2018.02.020","volume":"173","author":"TJ Mitchell","year":"2018","unstructured":"Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell 173, 611\u2013623.e17 (2018).","journal-title":"Cell"},{"key":"70517_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage, L., Eisen, T. & Maher, E. R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 15, 55\u201364 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"70517_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"70517_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the \u03b2-domain of the von Hippel\u2013Lindau protein. Nat. Cell Biol. 2, 423\u2013427 (2000).","journal-title":"Nat. Cell Biol."},{"key":"70517_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin","year":"2008","unstructured":"Kaelin, W. G. & Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30, 393\u2013402 (2008).","journal-title":"Mol. Cell"},{"key":"70517_CR15","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1002\/cncr.24238","volume":"115","author":"C-N Qian","year":"2009","unstructured":"Qian, C.-N., Huang, D., Wondergem, B. & Teh, B. T. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 115, 2282\u20132289 (2009).","journal-title":"Cancer"},{"key":"70517_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/2159-8290.CD-14-1507","volume":"5","author":"B Qiu","year":"2015","unstructured":"Qiu, B. et al. HIF2\u03b1-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 5, 652\u2013667 (2015).","journal-title":"Cancer Discov."},{"key":"70517_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","volume":"29","author":"AA Hakimi","year":"2016","unstructured":"Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104\u2013116 (2016).","journal-title":"Cancer Cell"},{"key":"70517_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01965-8","volume":"8","author":"W Du","year":"2017","unstructured":"Du, W. et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat. Commun. 8, 1769 (2017).","journal-title":"Nat. Commun."},{"key":"70517_CR19","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","volume":"278","author":"LH Hartwell","year":"1997","unstructured":"Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064\u20131068 (1997).","journal-title":"Science"},{"key":"70517_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"70517_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"70517_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"70517_CR23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"70517_CR24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.cell.2014.07.027","volume":"158","author":"L Jerby-Arnon","year":"2014","unstructured":"Jerby-Arnon, L. et al. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell 158, 1199\u20131209 (2014).","journal-title":"Cell"},{"key":"70517_CR25","doi-asserted-by":"publisher","first-page":"21441","DOI":"10.1073\/pnas.2000516117","volume":"117","author":"Y Xiao","year":"2020","unstructured":"Xiao, Y. et al. The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proc. Natl. Acad. Sci. 117, 21441\u201321449 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"70517_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2008.06.004","volume":"14","author":"S Turcotte","year":"2008","unstructured":"Turcotte, S. et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14, 90\u2013102 (2008).","journal-title":"Cancer Cell"},{"key":"70517_CR27","doi-asserted-by":"publisher","first-page":"16951","DOI":"10.18632\/oncotarget.4773","volume":"6","author":"NC Wolff","year":"2015","unstructured":"Wolff, N. C. et al. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget 6, 16951\u201316962 (2015).","journal-title":"Oncotarget"},{"key":"70517_CR28","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/onc.2016.272","volume":"36","author":"JM Thompson","year":"2017","unstructured":"Thompson, J. M. et al. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Oncogene 36, 1080\u20131089 (2017).","journal-title":"Oncogene"},{"key":"70517_CR29","doi-asserted-by":"publisher","first-page":"16484","DOI":"10.1073\/pnas.0806574105","volume":"105","author":"A Bommi-Reddy","year":"2008","unstructured":"Bommi-Reddy, A. et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL\u2212\/\u2212 cancer cells detected in a pilot synthetic lethal screen. Proc. Natl. Acad. Sci. 105, 16484\u201316489 (2008).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"70517_CR30","doi-asserted-by":"crossref","unstructured":"Chakraborty, A. A. et al. HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Sci. Transl. Med. 9, eaal5272 (2017).","DOI":"10.1126\/scitranslmed.aal5272"},{"key":"70517_CR31","doi-asserted-by":"crossref","unstructured":"Nicholson, H. E. et al. HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species. Sci. Signal. 12, eaay0482 (2019).","DOI":"10.1126\/scisignal.aay0482"},{"key":"70517_CR32","first-page":"1","volume":"0","author":"LJ Nelson","year":"2022","unstructured":"Nelson, L. J. et al. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma. Cell Cycle 0, 1\u201317 (2022).","journal-title":"Cell Cycle"},{"key":"70517_CR33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1158\/2159-8290.CD-19-0837","volume":"10","author":"L Hu","year":"2020","unstructured":"Hu, L. et al. TBK1 is a synthetic lethal target in cancer with VHL loss. Cancer Discov. 10, 460\u2013475 (2020).","journal-title":"Cancer Discov."},{"key":"70517_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1089\/crispr.2019.0018","volume":"2","author":"N Sun","year":"2019","unstructured":"Sun, N. et al. VHL synthetic lethality signatures uncovered by genotype-specific CRISPR-Cas9 screens. CRISPR J. 2, 230\u2013245 (2019).","journal-title":"CRISPR J."},{"key":"70517_CR35","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0895-822","volume":"1","author":"O Iliopoulos","year":"1995","unstructured":"Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1, 822\u2013826 (1995).","journal-title":"Nat. Med."},{"key":"70517_CR36","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"70517_CR37","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1534\/g3.117.041277","volume":"7","author":"T Hart","year":"2017","unstructured":"Hart, T. et al. Evaluation and design of genome-wide CRISPR\/SpCas9 knockout screens. G3 Genes Genomes Genet. 7, 2719\u20132727 (2017).","journal-title":"G3 Genes Genomes Genet."},{"key":"70517_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00809-3","volume":"13","author":"E Kim","year":"2021","unstructured":"Kim, E. & Hart, T. Improved analysis of CRISPR fitness screens and reduced off-target effects with the BAGEL2 gene essentiality classifier. Genome Med 13, 2 (2021).","journal-title":"Genome Med"},{"key":"70517_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0665-3","volume":"11","author":"M Colic","year":"2019","unstructured":"Colic, M. et al. Identifying chemogenetic interactions from CRISPR screens with drugZ. Genome Med. 11, 52 (2019).","journal-title":"Genome Med."},{"key":"70517_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol 15, 554 (2014).","journal-title":"Genome Biol"},{"key":"70517_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","volume":"539","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models. Nature 539, 107\u2013111 (2016).","journal-title":"Nature"},{"key":"70517_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1006\/viro.1993.1262","volume":"194","author":"E Ogawa","year":"1993","unstructured":"Ogawa, E. et al. Molecular cloning and characterization of PEBP2\u03b2, the heterodimeric partner of a novel drosophila runt-related DNA binding protein PEBP2\u03b1. Virology 194, 314\u2013331 (1993).","journal-title":"Virology"},{"key":"70517_CR43","doi-asserted-by":"publisher","DOI":"10.1242\/dev.148296","volume":"146","author":"R Mevel","year":"2019","unstructured":"Mevel, R., Draper, J. E., Lie-a-Ling, M., Kouskoff, V. & Lacaud, G. RUNX transcription factors: orchestrators of development. Development 146, dev148296 (2019).","journal-title":"Development"},{"key":"70517_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","volume":"236","author":"K Itoh","year":"1997","unstructured":"Itoh, K. et al. An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236, 313\u2013322 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"70517_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1128\/MCB.26.1.221-229.2006","volume":"26","author":"A Kobayashi","year":"2006","unstructured":"Kobayashi, A. et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell. Biol. 26, 221\u2013229 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"70517_CR46","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.molcel.2023.12.010","volume":"84","author":"L Hu","year":"2024","unstructured":"Hu, L. et al. Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma. Mol. Cell 84, 776\u2013790.e5 (2024).","journal-title":"Mol. Cell"},{"key":"70517_CR47","doi-asserted-by":"publisher","first-page":"39579","DOI":"10.1074\/jbc.M007350200","volume":"275","author":"Y-Y Tang","year":"2000","unstructured":"Tang, Y.-Y. et al. Energetic and functional contribution of residues in the core binding factor \u03b2 (CBF\u03b2) subunit to heterodimerization with CBF\u03b1. J. Biol. Chem. 275, 39579\u201339588 (2000).","journal-title":"J. Biol. Chem."},{"key":"70517_CR48","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.ccell.2022.11.001","volume":"40","author":"R Li","year":"2022","unstructured":"Li, R. et al. Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Cancer Cell 40, 1583\u20131599.e10 (2022).","journal-title":"Cancer Cell"},{"key":"70517_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36\u201349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"70517_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa2630","volume":"347","author":"S Liu","year":"2015","unstructured":"Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347, aaa2630 (2015).","journal-title":"Science"},{"key":"70517_CR51","doi-asserted-by":"publisher","first-page":"E3403","DOI":"10.1073\/pnas.1603269113","volume":"113","author":"B Zhao","year":"2016","unstructured":"Zhao, B. et al. Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins. Proc. Natl. Acad. Sci. 113, E3403\u2013E3412 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"70517_CR52","doi-asserted-by":"publisher","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","volume":"41","author":"I Rusinova","year":"2013","unstructured":"Rusinova, I. et al. INTERFEROME v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040\u2013D1046 (2013).","journal-title":"Nucleic Acids Res."},{"key":"70517_CR53","doi-asserted-by":"publisher","first-page":"a028555","DOI":"10.1101\/cshperspect.a028555","volume":"10","author":"GR Stark","year":"2018","unstructured":"Stark, G. R., Cheon, H. & Wang, Y. Responses to cytokines and interferons that depend upon JAKs and STATs. Cold Spring Harb. Perspect. Biol. 10, a028555 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"70517_CR54","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1128\/JVI.80.2.1032-1037.2006","volume":"80","author":"VR DeFilippis","year":"2006","unstructured":"DeFilippis, V. R. et al. Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection. J. Virol. 80, 1032\u20131037 (2006).","journal-title":"J. Virol."},{"key":"70517_CR55","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/v11030246","volume":"11","author":"CL Ashley","year":"2019","unstructured":"Ashley, C. L., Abendroth, A., McSharry, B. P. & Slobedman, B. Interferon-independent upregulation of interferon-stimulated genes during human cytomegalovirus infection is dependent on IRF3 expression. Viruses 11, 246 (2019).","journal-title":"Viruses"},{"key":"70517_CR56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/nar\/gkz1112","volume":"48","author":"M Csumita","year":"2020","unstructured":"Csumita, M. et al. Specific enhancer selection by IRF3, IRF5 and IRF9 is determined by ISRE half-sites, 5\u2032 and 3\u2032 flanking bases, collaborating transcription factors and the chromatin environment in a combinatorial fashion. Nucleic Acids Res. 48, 589\u2013604 (2020).","journal-title":"Nucleic Acids Res."},{"key":"70517_CR57","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/gene.2011.21","volume":"12","author":"S Ning","year":"2011","unstructured":"Ning, S., Pagano, J. S. & Barber, G. N. IRF7: activation, regulation, modification and function. Genes Immun. 12, 399\u2013414 (2011).","journal-title":"Genes Immun."},{"key":"70517_CR58","doi-asserted-by":"publisher","first-page":"9698","DOI":"10.1074\/jbc.M310616200","volume":"279","author":"M Mori","year":"2004","unstructured":"Mori, M. et al. Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. J. Biol. Chem. 279, 9698\u20139702 (2004).","journal-title":"J. Biol. Chem."},{"key":"70517_CR59","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41586-019-1006-9","volume":"567","author":"X Gui","year":"2019","unstructured":"Gui, X. et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature 567, 262\u2013266 (2019).","journal-title":"Nature"},{"key":"70517_CR60","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786\u2013791 (2013).","journal-title":"Science"},{"key":"70517_CR61","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature14156","volume":"520","author":"AP West","year":"2015","unstructured":"West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 520, 553\u2013557 (2015).","journal-title":"Nature"},{"key":"70517_CR62","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ncb3586","volume":"19","author":"S Gl\u00fcck","year":"2017","unstructured":"Gl\u00fcck, S. et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat. Cell Biol. 19, 1061\u20131070 (2017).","journal-title":"Nat. Cell Biol."},{"key":"70517_CR63","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1126\/science.aav4011","volume":"366","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science 366, 1531\u20131536 (2019).","journal-title":"Science"},{"key":"70517_CR64","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","volume":"21","author":"K-P Hopfner","year":"2020","unstructured":"Hopfner, K.-P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS\u2013STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501\u2013521 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"70517_CR65","doi-asserted-by":"publisher","first-page":"e49799","DOI":"10.15252\/embr.201949799","volume":"21","author":"JS Riley","year":"2020","unstructured":"Riley, J. S. & Tait, S. W. Mitochondrial DNA in inflammation and immunity. EMBO Rep. 21, e49799 (2020).","journal-title":"EMBO Rep."},{"key":"70517_CR66","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding, S. M. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466\u2013470 (2017).","journal-title":"Nature"},{"key":"70517_CR67","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie, K. J. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461\u2013465 (2017).","journal-title":"Nature"},{"key":"70517_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110285","volume":"27","author":"M Jiao","year":"2024","unstructured":"Jiao, M. et al. VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway. iScience 27, 110285 (2024).","journal-title":"iScience"},{"key":"70517_CR69","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1158\/0008-5472.CAN-15-3139","volume":"76","author":"E Cherkasova","year":"2016","unstructured":"Cherkasova, E. et al. Detection of an immunogenic HERV-E envelope with selective expression in clear cell kidney cancer. Cancer Res. 76, 2177\u20132185 (2016).","journal-title":"Cancer Res."},{"key":"70517_CR70","doi-asserted-by":"crossref","unstructured":"Panda, A. et al. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3, e121522 (2018).","DOI":"10.1172\/jci.insight.121522"},{"key":"70517_CR71","doi-asserted-by":"crossref","unstructured":"Weyerer, V. et al. Endogenous retroviral\u2013K envelope is a novel tumor antigen and prognostic indicator of renal cell carcinoma. Front. Oncol. 11, 657187 (2021).","DOI":"10.3389\/fonc.2021.657187"},{"key":"70517_CR72","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.cell.2025.01.046","volume":"188","author":"Q Jiang","year":"2025","unstructured":"Jiang, Q. et al. HIF regulates multiple translated endogenous retroviruses: implications for cancer immunotherapy. Cell 188, 1807\u20131827.e34 (2025).","journal-title":"Cell"},{"key":"70517_CR73","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1128\/jvi.67.4.2408-2411.1993","volume":"67","author":"IN Melnikova","year":"1993","unstructured":"Melnikova, I. N., Crute, B. E., Wang, S. & Speck, N. A. Sequence specificity of the core-binding factor. J. Virol. 67, 2408\u20132411 (1993).","journal-title":"J. Virol."},{"key":"70517_CR74","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-020-2493-4","volume":"583","author":"The ENCODE Project Consortium","year":"2020","unstructured":"The ENCODE Project Consortium Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature 583, 699\u2013710 (2020).","journal-title":"Nature"},{"key":"70517_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005884","volume":"12","author":"MH Shin","year":"2016","unstructured":"Shin, M. H. et al. A RUNX2-mediated epigenetic regulation of the survival of p53 defective cancer cells. PLOS Genet. 12, e1005884 (2016).","journal-title":"PLOS Genet."},{"key":"70517_CR76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature10693","volume":"481","author":"S J\u00e4ger","year":"2012","unstructured":"J\u00e4ger, S. et al. Vif hijacks CBF-\u03b2 to degrade APOBEC3G and promote HIV-1 infection. Nature 481, 371\u2013375 (2012).","journal-title":"Nature"},{"key":"70517_CR77","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature10718","volume":"481","author":"W Zhang","year":"2012","unstructured":"Zhang, W., Du, J., Evans, S. L., Yu, Y. & Yu, X.-F. T-cell differentiation factor CBF-\u03b2 regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481, 376\u2013379 (2012).","journal-title":"Nature"},{"key":"70517_CR78","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.molcel.2012.12.012","volume":"49","author":"DY Kim","year":"2013","unstructured":"Kim, D. Y. et al. CBF\u03b2 stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell 49, 632\u2013644 (2013).","journal-title":"Mol. Cell"},{"key":"70517_CR79","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1158\/0008-5472.CAN-19-3870","volume":"80","author":"N Rooney","year":"2020","unstructured":"Rooney, N. et al. RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome. Cancer Res. 80, 2325\u20132339 (2020).","journal-title":"Cancer Res."},{"key":"70517_CR80","first-page":"609","volume":"43","author":"B Liu","year":"2020","unstructured":"Liu, B., Liu, J., Yu, H., Wang, C. & Kong, C. Transcription factor RUNX2 regulates epithelial\u2011mesenchymal transition and progression in renal cell carcinomas. Oncol. Rep. 43, 609\u2013616 (2020).","journal-title":"Oncol. Rep."},{"key":"70517_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03617-8","volume":"12","author":"C-Y Wu","year":"2021","unstructured":"Wu, C.-Y. et al. A Zic2\/Runx2\/NOLC1 signaling axis mediates tumor growth and metastasis in clear cell renal cell carcinoma. Cell Death Dis. 12, 1\u201311 (2021).","journal-title":"Cell Death Dis."},{"key":"70517_CR82","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1248\/bpb.b22-00451","volume":"45","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Ren, Z., Liu, B. & Wei, S. RUNX2 mediates renal cell carcinoma invasion through Calpain2. Biol. Pharm. Bull. 45, 1653\u20131659 (2022).","journal-title":"Biol. Pharm. Bull."},{"key":"70517_CR83","doi-asserted-by":"crossref","unstructured":"Xue, J. et al. RUNX1\/miR-582-5p pathway regulates the tumor progression in clear cell renal cell carcinoma by targeting COL5A1. Front. Oncol. 11, 610992 (2021).","DOI":"10.3389\/fonc.2021.610992"},{"key":"70517_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10102-6","volume":"10","author":"N Malik","year":"2019","unstructured":"Malik, N. et al. The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription. Nat. Commun. 10, 2071 (2019).","journal-title":"Nat. Commun."},{"key":"70517_CR85","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/emboj\/20.4.723","volume":"20","author":"G Huang","year":"2001","unstructured":"Huang, G. et al. Dimerization with PEBP2\u03b2 protects RUNX1\/AML1 from ubiquitin\u2013proteasome-mediated degradation. EMBO J. 20, 723\u2013733 (2001).","journal-title":"EMBO J."},{"key":"70517_CR86","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ebiom.2016.04.032","volume":"8","author":"A Illendula","year":"2016","unstructured":"Illendula, A. et al. Small molecule inhibitor of CBF\u03b2-RUNX binding for RUNX transcription factor driven cancers. EBioMedicine 8, 117\u2013131 (2016).","journal-title":"EBioMedicine"},{"key":"70517_CR87","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1172\/JCI91788","volume":"127","author":"K Morita","year":"2017","unstructured":"Morita, K. et al. Genetic regulation of the RUNX transcription factor family has antitumor effects. J. Clin. Invest. 127, 2815\u20132828 (2017).","journal-title":"J. Clin. Invest."},{"key":"70517_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24969-w","volume":"8","author":"Y Mitsuda","year":"2018","unstructured":"Mitsuda, Y. et al. RUNX1 positively regulates the ErbB2\/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci. Rep. 8, 6423 (2018).","journal-title":"Sci. Rep."},{"key":"70517_CR89","first-page":"1","volume":"5","author":"EY Hattori","year":"2022","unstructured":"Hattori, E. Y. et al. A RUNX-targeted gene switch-off approach modulates the BIRC5\/PIF1-p21 pathway and reduces glioblastoma growth in mice. Commun. Biol. 5, 1\u201311 (2022).","journal-title":"Commun. Biol."},{"key":"70517_CR90","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbrc.2022.06.090","volume":"620","author":"Y Matsui","year":"2022","unstructured":"Matsui, Y. et al. Chlorambucil-conjugated PI-polyamides (Chb-M\u2019), a transcription inhibitor of RUNX family, has an anti-tumor activity against SHH-type medulloblastoma with p53 mutation. Biochem. Biophys. Res. Commun. 620, 150\u2013157 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"70517_CR91","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.1021\/acs.jmedchem.4c00315","volume":"67","author":"Y Hirose","year":"2024","unstructured":"Hirose, Y. et al. Chb-M\u2032, an inhibitor of the RUNX family binding to DNA, induces apoptosis in p53-mutated non-small cell lung cancer and inhibits tumor growth and repopulation in vivo. J. Med. Chem. 67, 9165\u20139172 (2024).","journal-title":"J. Med. Chem."},{"key":"70517_CR92","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fcell.2017.00111","volume":"5","author":"DC Bellissimo","year":"2017","unstructured":"Bellissimo, D. C. & Speck, N. A. RUNX1 mutations in inherited and sporadic leukemia. Front. Cell Dev. Biol. 5, 111 (2017).","journal-title":"Front. Cell Dev. Biol."},{"key":"70517_CR93","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1172\/JCI68557","volume":"123","author":"S Goyama","year":"2013","unstructured":"Goyama, S. et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J. Clin. Invest. 123, 3876\u20133888 (2013).","journal-title":"J. Clin. Invest."},{"key":"70517_CR94","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12185-008-0121-4","volume":"88","author":"T Yokomizo","year":"2008","unstructured":"Yokomizo, T. et al. Genetic evidence of PEBP2\u03b2-independent activation of Runx1 in the murine embryo. Int. J. Hematol. 88, 134\u2013138 (2008).","journal-title":"Int. J. Hematol."},{"key":"70517_CR95","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2013-10-531988","volume":"124","author":"E Bresciani","year":"2014","unstructured":"Bresciani, E. et al. CBF\u03b2 and RUNX1 are required at 2 different steps during the development of hematopoietic stem cells in zebrafish. Blood 124, 70\u201378 (2014).","journal-title":"Blood"},{"key":"70517_CR96","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/emboj\/18.6.1609","volume":"18","author":"WY Kim","year":"1999","unstructured":"Kim, W. Y. et al. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J. 18, 1609\u20131620 (1999).","journal-title":"EMBO J."},{"key":"70517_CR97","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.celrep.2013.11.025","volume":"5","author":"LP Vu","year":"2013","unstructured":"Vu, L. P. et al. PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. Cell Rep. 5, 1625\u20131638 (2013).","journal-title":"Cell Rep."},{"key":"70517_CR98","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1101\/gad.192054.112","volume":"26","author":"H Huang","year":"2012","unstructured":"Huang, H. et al. A Src family kinase\u2013Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation. Genes Dev. 26, 1587\u20131601 (2012).","journal-title":"Genes Dev."},{"key":"70517_CR99","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1074\/jbc.275.1.651","volume":"275","author":"B Lutterbach","year":"2000","unstructured":"Lutterbach, B. et al. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J. Biol. Chem. 275, 651\u2013656 (2000).","journal-title":"J. Biol. Chem."},{"key":"70517_CR100","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1128\/MCB.24.3.1033-1043.2004","volume":"24","author":"Y Imai","year":"2004","unstructured":"Imai, Y. et al. The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1. Mol. Cell. Biol. 24, 1033\u20131043 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"70517_CR101","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1101\/gad.1632608","volume":"22","author":"X Zhao","year":"2008","unstructured":"Zhao, X. et al. Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev 22, 640\u2013653 (2008).","journal-title":"Genes Dev"},{"key":"70517_CR102","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581\u2013594.e12 (2018).","journal-title":"Cell"},{"key":"70517_CR103","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","volume":"3","author":"FM Barriga","year":"2022","unstructured":"Barriga, F. M. et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nat. Cancer 3, 1367\u20131385 (2022).","journal-title":"Nat. Cancer"},{"key":"70517_CR104","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s43018-023-00584-1","volume":"4","author":"L Perelli","year":"2023","unstructured":"Perelli, L. et al. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat. Cancer 4, 984\u20131000 (2023).","journal-title":"Nat. Cancer"},{"key":"70517_CR105","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.37925","volume":"7","author":"L Liao","year":"2018","unstructured":"Liao, L. et al. Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. eLife 7, e37925 (2018).","journal-title":"eLife"},{"key":"70517_CR106","doi-asserted-by":"publisher","first-page":"215885","DOI":"10.1016\/j.canlet.2022.215885","volume":"547","author":"LE Langbein","year":"2022","unstructured":"Langbein, L. E. et al. BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma. Cancer Lett. 547, 215885 (2022).","journal-title":"Cancer Lett."},{"key":"70517_CR107","doi-asserted-by":"publisher","first-page":"C1417","DOI":"10.1152\/ajpcell.00255.2022","volume":"323","author":"LE Langbein","year":"2022","unstructured":"Langbein, L. E., Hajjar, R. E., Kim, W. Y. & Yang, H. The convergence of tumor suppressors on interferon pathway in kidney cancer and its therapeutic implication. Am. J. Physiol. Cell Physiol. 323, C1417\u2013C1429 (2022).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"70517_CR108","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1158\/2159-8290.CD-24-0499","volume":"15","author":"\u00c1 Fern\u00e1ndez-Sanrom\u00e1n","year":"2025","unstructured":"Fern\u00e1ndez-Sanrom\u00e1n, \u00c1 et al. Tracking nongenetic evolution from primary to metastatic ccRCC: TRACERx renal. Cancer Discov. 15, 530\u2013552 (2025).","journal-title":"Cancer Discov."},{"key":"70517_CR109","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.3390\/cancers13112695","volume":"13","author":"A Amouzegar","year":"2021","unstructured":"Amouzegar, A., Chelvanambi, M., Filderman, J. N., Storkus, W. J. & Luke, J. J. STING agonists as cancer therapeutics. Cancers 13, 2695 (2021).","journal-title":"Cancers"},{"key":"70517_CR110","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","volume":"25","author":"JB Hines","year":"2023","unstructured":"Hines, J. B., Kacew, A. J. & Sweis, R. F. The development of STING agonists and emerging results as a cancer immunotherapy. Curr. Oncol. Rep. 25, 189\u2013199 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"70517_CR111","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674\u2013678 (2008).","journal-title":"Nature"},{"key":"70517_CR112","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.immuni.2008.09.003","volume":"29","author":"B Zhong","year":"2008","unstructured":"Zhong, B. et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29, 538\u2013550 (2008).","journal-title":"Immunity"},{"key":"70517_CR113","doi-asserted-by":"publisher","first-page":"85049","DOI":"10.18632\/oncotarget.13183","volume":"7","author":"Y-Y Wang","year":"2016","unstructured":"Wang, Y.-Y., Jin, R., Zhou, G.-P. & Xu, H.-G. Mechanisms of transcriptional activation of the stimulator of interferon genes by transcription factors CREB and c-Myc. Oncotarget 7, 85049\u201385057 (2016).","journal-title":"Oncotarget"},{"key":"70517_CR114","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2326-6066.CIR-21-0826","volume":"10","author":"K Lee","year":"2022","unstructured":"Lee, K. et al. Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer. Cancer Immunol. Res. 10, 829\u2013843 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"70517_CR115","doi-asserted-by":"publisher","first-page":"121336","DOI":"10.1016\/j.lfs.2022.121336","volume":"314","author":"L-Y Chen","year":"2023","unstructured":"Chen, L.-Y., Pang, X.-Y., Chen, C. & Xu, H.-G. NF-\u03baB regulates the expression of STING via alternative promoter usage. Life Sci. 314, 121336 (2023).","journal-title":"Life Sci."},{"key":"70517_CR116","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1101\/gad.350418.123","volume":"37","author":"AU Zezulin","year":"2023","unstructured":"Zezulin, A. U. et al. RUNX1 is required in granulocyte\u2013monocyte progenitors to attenuate inflammatory cytokine production by neutrophils. Genes Dev. 37, 605\u2013620 (2023).","journal-title":"Genes Dev."},{"key":"70517_CR117","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nrmicro3449","volume":"13","author":"T Doyle","year":"2015","unstructured":"Doyle, T., Goujon, C. & Malim, M. H. HIV-1 and interferons: who\u2019s interfering with whom? Nat. Rev. Microbiol. 13, 403\u2013413 (2015).","journal-title":"Nat. Rev. Microbiol."},{"key":"70517_CR118","doi-asserted-by":"crossref","unstructured":"Soper, A. et al. Type I interferon responses by HIV-1 infection: association with disease progression and control. Front. Immunol. 8, 1823 (2018).","DOI":"10.3389\/fimmu.2017.01823"},{"key":"70517_CR119","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nmeth.2812","volume":"11","author":"F Heigwer","year":"2014","unstructured":"Heigwer, F., Kerr, G. & Boutros, M. E-CRISP: fast CRISPR target site identification. Nat. Methods 11, 122\u2013123 (2014).","journal-title":"Nat. Methods"},{"key":"70517_CR120","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41592-020-0850-8","volume":"17","author":"G Michlits","year":"2020","unstructured":"Michlits, G. et al. Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles. Nat. Methods 17, 708\u2013716 (2020).","journal-title":"Nat. Methods"},{"key":"70517_CR121","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"70517_CR122","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.26693","volume":"6","author":"H-T Huang","year":"2017","unstructured":"Huang, H.-T. et al. MELK is not necessary for the proliferation of basal-like breast cancer cells. eLife 6, e26693 (2017).","journal-title":"eLife"},{"key":"70517_CR123","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nmeth.3972","volume":"13","author":"F Port","year":"2016","unstructured":"Port, F. & Bullock, S. L. Augmenting CRISPR applications in Drosophila with tRNA-flanked Cas9 and Cpf1 sgRNAs. Nat. Methods 13, 852\u2013854 (2016).","journal-title":"Nat. Methods"},{"key":"70517_CR124","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41588-021-00887-y","volume":"53","author":"BM Ortmann","year":"2021","unstructured":"Ortmann, B. M. et al. The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes. Nat. Genet. 53, 1022\u20131035 (2021).","journal-title":"Nat. Genet."},{"key":"70517_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17862-6","volume":"11","author":"PSJ Bailey","year":"2020","unstructured":"Bailey, P. S. J. et al. ABHD11 maintains 2-oxoglutarate metabolism by preserving functional lipoylation of the 2-oxoglutarate dehydrogenase complex. Nat. Commun. 11, 4046 (2020).","journal-title":"Nat. Commun."},{"key":"70517_CR126","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","volume":"179","author":"DJ Clark","year":"2019","unstructured":"Clark, D. J. et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179, 964\u2013983.e31 (2019).","journal-title":"Cell"},{"key":"70517_CR127","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccell.2022.12.001","volume":"41","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell 41, 139\u2013163.e17 (2023).","journal-title":"Cancer Cell"},{"key":"70517_CR128","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst 1, 417\u2013425 (2015).","journal-title":"Cell Syst"},{"key":"70517_CR129","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70517-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70517-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70517-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:03:15Z","timestamp":1777334595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70517-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70517"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70517-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.03.610968","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3841"}}